P1.13-20 MET Protein Expression and Activation During Targeted Therapy in EGFR Mutated Lung Adenocarcinoma

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.877
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P1.13-12 EGFR Therapy in ASCL1 Positive Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Lung Adenocarcinoma: Guiding EGFR-targeted Therapy and Beyond

Modern Pathology
Forensic MedicinePathology
2008English

Proteogenomic Systems Analysis Identifies Targeted Therapy Resistance Mechanisms in EGFR-mutated Lung Cancer

International Journal of Cancer
Cancer ResearchOncology
2018English

Risk Factors of Brain Metastasis During the Course of EGFR-TKIs Therapy for Patients With EGFR-mutated Advanced Lung Adenocarcinoma

Oncotarget
Oncology
2016English

ALK Fusion Protein Expression in Lung Adenocarcinoma and Its Correlation With EGFR Protein Expression

Madridge Journal of Oncogenesis
2018English

MET-EGFR Dimerization in Lung Adenocarcinoma Is Dependent on EGFR Mtations and Altered by MET Kinase Inhibition

PLoS ONE
Multidisciplinary
2017English

DNA Damage Repair Protein Expression and EGFR Gene Status in Lung Adenocarcinoma Patients

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2016English

18f-Fluorodeoxyglucose Uptake Predicts MET Expression in Lung Adenocarcinoma

OncoTargets and Therapy
OncologyPharmacology
2017English

Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy